Skip to main content

Table 1 Characteristics between patients who did or did not experience recurrences

From: High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study

 

Control group

Case group

 

n = 121

Percentage

n = 121

Percentage

P value

Age (years)

     

 mean (range)

51.4 (28–89)

51.6 (27–94)

0.738*

 <40

15

12.4

19

15.7

0.725

 40–59

87

71.9

82

67.8

 

 >60

19

15.7

20

16.5

 

AJCC stage (pathological)

     

 I

24

19.8

24

19.8

1.000

 IIA

33

27.3

33

27.3

 

 IIB

18

14.9

18

14.9

 

 IIIA

20

16.5

20

16.5

 

 IIIB

2

1.7

2

1.7

 

 IIIC

24

19.8

24

19.8

 

Tumor size (mm)

     

 0–10

19

15.7

19

15.7

0.911

 10 − 19

19

15.7

22

18.2

 

 20 − 50

68

56.2

63

52.1

 

 >50

15

12.4

17

14.0

 

Positive axillary nodes

     

 None

47

38.8

49

40.5

0.956

 1–3

32

26.4

32

26.4

 

 >4

42

34.7

40

33.1

 

Margin

     

 Negative

112

92.6

106

87.6

0.197

 Positive

9

7.4

15

12.4

 

Estrogen/progesterone receptor status

     

 Negative

46

38.0

44

36.4

0.790

 Positive

75

62.0

77

63.6

 

Her2 statusa

     

 Negative

92

76.0

88

72.7

0.556

 Positive

29

24.0

33

27.3

 

Triple-negative cancer

     

 Negative

100

82.6

95

78.5

0.417

 Positive

21

17.4

26

21.5

 

MBD quartiles

     

 1 (0–25%)

29

24.0

10

8.3

0.023

 2 (25–50%)

53

43.8

59

48.8

 

 3 (50–75%)

32

26.4

41

33.9

 

 4 (75–100%)

7

5.8

11

9.1

 

Adjuvant chemotherapy

     

 No

26

21.5

21

17.4

0.417

 Yes

95

78.5

100

82.6

 

Adjuvant hormone therapy

     

 No

47

38.8

50

41.3

0.694

 Yes

74

61.2

71

58.7

 

Adjuvant target therapy

     

 No

100

82.6

102

84.3

0.729

 Yes

21

17.4

19

15.7

 

Adjuvant radiotherapy

     

 No

59

48.8

64

52.9

0.520

 Yes

62

51.2

57

47.1

 

BMI (kg/m2)

     

 mean (range)

24.0 (16.2–35.4)

23.1 (15.4–38.1)

0.272*

 Normal (<25)

85

70.2

80

64.5

0.627

 Overweight (25–30)

28

23.1

33

27.3

 

 Obese (>30)

8

6.6

10

8.3

 
  1. a Human epidermal growth factor receptor 2 (Her2) status indicated all Her2 (3+)-positive tumors and Her2 (2+)- positive tumors with Her2 amplification investigated by fluorescence in situ hybridization; ratio ≥ 2. AJCC American Joint Committee on Cancer, MBD mammographic breast density, BMI body mass index. *Significance tested using paired Student’s t test. Significance tested using Pearson’s chi-square test